Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
27 September 2021 | Story Leonie Bolleurs | Photo Supplied
Dr Frikkie Maré is serving as one of the directors of the non-profit organisation, the Agri Relief Foundation (ARF).

The agricultural sector is used to facing events of abnormal impact, including floods, droughts, veld fires, and disease outbreaks. Even if it is possible to prepare against any of these risks by taking proper measures, for instance by having a farm emergency plan in place or by securing property properly, there are times when it is not possible or practical for the modern-day South African farmer to proactively manage all the risks they are facing.

It is in times like these that the newly established body, the Agri Relief Foundation (ARF), provides an invaluable service to the agricultural sector. 

Dr Frikkie Maré, Senior Lecturer in the Department of Agricultural Economics at the University of the Free State (UFS), is one of the directors of this non-profit organisation, which focuses on assisting agricultural producers in need. 

This initiative is the brainchild of a number of businesses in the agricultural sector.

He says although there are many institutions in South Africa assisting farmers, most of the current initiatives are geared towards large-scale disasters, such as severe droughts, floods, unpreventable pests and diseases, and veld fires that affect many producers.  

Benefiting the wider society

According to Dr Maré, the ARF will focus on helping individual agricultural producers who are in need; both financially and otherwise.  This may include elements such as the loss of grazing due to brown locust, assistance after a farm attack or murder to ensure the day-to-day running of the farm, and localised natural disasters such as floods, hail, severe cold, or fire.

The group of directors plays a key role in screening the applications for assistance and deciding, based on merit and the availability of resources, who they can assist.

Besides the direct benefit to the farmer, this initiative also adds value to the wider society. “When the sustainability of an agricultural producer is under threat, it also threatens the livelihoods of his/her workers and their families, the rural economy of the nearest town where they purchase production inputs and general groceries, as well as society at large, as less food and/or fibre will be produced.  The assistance of the ARF will therefore ripple out to a much larger level than only the agricultural producer,” explains Dr Maré. 

A learning experience

There is also a benefit for the university. In the classroom, Dr Maré will be able to share any knowledge he is gaining in this process with his students. “Agricultural Economics is fundamentally about ensuring the long-term sustainability of agricultural production through concepts, including but not limited to, production economics, natural resource economics, agricultural management, and marketing.  My involvement in the ARF will provide examples of what can go wrong in terms of primary production that threatens the sustainability of the enterprise and what can be done to assist,” he says. 

Any business or individual can contribute to this noble cause. Financial contributions as well as physical products such as transport, fuel, animal feed, and legal services are welcome. 

Dr Maré says they have already received contributions from companies such as Zoetis (animal health), which sponsor a part of their profit from certain products to the foundation on a continuous basis. Lavendula (animal feed) also sponsored the proceeds of a farmers’ information day.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept